De Motu Cordis is developing a medical device platform, utilising our patented inhalation technology to provide emergency treatment solutions for a number of indications.


Anaphylaxis is a severe allergic reaction that occurs after exposure to an allergen. It should be treated as a medical emergency as it can be potentially life threatening.

The onset of symptoms can occur rapidly and include:

  • Swelling or tightness of the throat
  • Difficulty breathing or wheezing
  • Swelling of the tongue, face, or lips
  • Dizziness or unconsciousness
  • Young children may become pale or floppy
  • Hives or reddening of the skin
  • Abdominal pain or vomiting

The most common triggers for anaphylactic shock include food, insect venom and medicines with the severity of reactions varying between individuals.

Epinephrine is the first line of treatment, rapidly reversing the effects of anaphylaxis.

The current standard is to administer the epinephrine via intramuscular injection as soon as possible. In a community setting this can be injected via an auto-injector, which is administered by the patient themselves or a bystander.

  • The majority of consumers do not carry their auto-injectors regularly due to their size and storage requirements
  • Parents/Caregivers and patients are hesitant to use their auto-injectors because of a fear of needles
  • When auto-injectors are used, they are commonly misused leading to injury and poor treatment outcomes
  • Time to peak plasma concentration is slow, on average absorption takes eighteen minutes.*

* In Phase 1 clinical studies testing inhalation delivery of DMC’s proprietary epinephrine formulation, plasma epinephrine concentrations reached Cmax 8 times faster compared to a widely used autoinjector.

De Motu Cordis has conducted multiple market research projects in the US.

Some key observations are captured below.

0 %
About one third had just one exposure


0 in 4

exposures resulted in more than one epinephrine dose

0 %

of adults have anxiety as a diagnosed comorbidity

Among these patients, there are indicators showing that epinephrine via auto-injector is viewed as a last-resort therapy…

0 in 4

try another approach before using epinephrine

Rationale for Not Using Epinephrine Auto-Injector in Recent Exposure Event

(% patients)

Tried to avoid having to use an injection

No Data Found

Symptoms did not seem severe enough, to need to use epinephrine

No Data Found

Epinephrine is the drug to treat severe allergic reactions including anaphylaxis, and commonly administered via intramuscular injection.

  • A report in the Journal of Allergy and Clinical Immunology (JACI) estimates that 1 in 50 residents in the United States may be at risk of an anaphylactic reaction. 1

  • Though it is also suggested that the prevalence is much high than that with The Allergy and Asthma Foundation estimating anaphylaxis occurs in about 5%, or 1 in 20 Americans. 2

  • IQVIA prescription data for auto-injectors in the USA estimates that approximately only 4 million people have a prescription.

Prevalence and prescriptions for Anaphylaxis in the USA and EU

No Data Found

  • Epidemiology data from Europe suggests that around 4% of the general population has experienced an anaphylactic episode.
  • IQVIA prescription data for auto-injectors in Europe estimates that approximately only 10% of eligible persons receive them.
  • According to the European Anaphylaxis Registry, less than 15% of anaphylaxis episodes are treated with an auto-injector

Visit the solutions page to see how DMC is addressing anaphylaxis

Quick facts about anaphylaxis

# 0
Australia is the allergy capital of the world


food induced anaphylactic reactions in the US each year


$ 0 B
cost to the US economy each year due to food allergies

Up to

0 %
of adrenaline auto-injectors are used incorrectly